GPP
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m
The deal focuses on T cell-based therapies for autoimmune disease
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide